Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000013886
JPRN-UMIN000013886
Recruiting
Phase 2

A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer - A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer

Tokyo Women's Medical University0 sites30 target enrollmentMay 6, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsBreast cancer

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Breast cancer
Sponsor
Tokyo Women's Medical University
Enrollment
30
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 6, 2014
End Date
April 30, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Tokyo Women's Medical University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Severe complications history of hypersensitivity reaction for important drug in this study Bilateral breast cancer Inflammatory breast cancer Pregnant or nursing women

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab for node-positive breast cancerbreast cancer
JPRN-UMIN000007648Tokyo Women's Medical University56
Active, not recruiting
Not Applicable
Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib followed by paclitaxel (P) + sorafenib in women with previously untreated primary breast cancer - SofiaWomen with previously untreated primary breast cancer.MedDRA version: 9.1Level: LLTClassification code 10057654Term: Breast cancer female
EUCTR2007-000124-41-DEGBG Forschungs GmbH36
Completed
Phase 2
Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancerBreast cancer
JPRN-UMIN000014163ational Cancer Center Hospital43
Completed
Phase 2
Phase II trial of Epirubicin / Cyclophosphamide (EC) followed by Nab-paclitaxel as neoadjuvant chemotherapy for node positive breast cancerBreast Cancer
JPRN-UMIN000009853Dokkyo Medical University23
Completed
Phase 2
Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast CancerBreast Cancer
NCT00548899German Breast Group36